Cargando…
Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada
BACKGROUND: Prostate cancer is the most frequently reported cancer in males in Europe, and is associated with substantial morbidity and mortality. The aim of the current review was to characterize the clinical, economic and humanistic burden of disease associated with prostate cancer in France, Germ...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421711/ https://www.ncbi.nlm.nih.gov/pubmed/30885200 http://dx.doi.org/10.1186/s12894-019-0448-6 |
_version_ | 1783404280252727296 |
---|---|
author | Smith-Palmer, J. Takizawa, C. Valentine, W. |
author_facet | Smith-Palmer, J. Takizawa, C. Valentine, W. |
author_sort | Smith-Palmer, J. |
collection | PubMed |
description | BACKGROUND: Prostate cancer is the most frequently reported cancer in males in Europe, and is associated with substantial morbidity and mortality. The aim of the current review was to characterize the clinical, economic and humanistic burden of disease associated with prostate cancer in France, Germany, the UK and Canada. METHODS: Literature searches were conducted using the PubMed, EMBASE and Cochrane Library databases to identify studies reporting incidence and/or mortality rates, costs and health state utilities associated with prostate cancer in the settings of interest. For inclusion, studies were required to be published in English in full-text form from 2006 onwards. RESULTS: Incidence studies showed that in all settings the incidence of prostate cancer has increased substantially over the past two decades, driven in part by increased uptake of prostate specific antigen (PSA) screening leading to earlier identification of tumors, but which has also led to over-treatment, compounding the economic burden of disease. Mortality rates have declined over the same time frame, driven by earlier detection and improvements in treatment. Both prostate cancer itself, as well as treatment and treatment-related complications, are associated with reduced quality of life. CONCLUSIONS: Prostate cancer is associated with a significant clinical and economic burden, whilst earlier detection and aggressive treatment is associated with improved survival, over-treatment of men with indolent tumors compounds the already significant burden of disease and treatment can lead to long-term side effects including impotence and impaired urinary and/or bowel function. There is currently an unmet clinical need for diagnostic and/or prognostic tools that facilitate personalized prostate cancer treatment, and potentially reduce the clinical, economic and humanistic burden of invasive cancer treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12894-019-0448-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6421711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64217112019-03-28 Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada Smith-Palmer, J. Takizawa, C. Valentine, W. BMC Urol Research Article BACKGROUND: Prostate cancer is the most frequently reported cancer in males in Europe, and is associated with substantial morbidity and mortality. The aim of the current review was to characterize the clinical, economic and humanistic burden of disease associated with prostate cancer in France, Germany, the UK and Canada. METHODS: Literature searches were conducted using the PubMed, EMBASE and Cochrane Library databases to identify studies reporting incidence and/or mortality rates, costs and health state utilities associated with prostate cancer in the settings of interest. For inclusion, studies were required to be published in English in full-text form from 2006 onwards. RESULTS: Incidence studies showed that in all settings the incidence of prostate cancer has increased substantially over the past two decades, driven in part by increased uptake of prostate specific antigen (PSA) screening leading to earlier identification of tumors, but which has also led to over-treatment, compounding the economic burden of disease. Mortality rates have declined over the same time frame, driven by earlier detection and improvements in treatment. Both prostate cancer itself, as well as treatment and treatment-related complications, are associated with reduced quality of life. CONCLUSIONS: Prostate cancer is associated with a significant clinical and economic burden, whilst earlier detection and aggressive treatment is associated with improved survival, over-treatment of men with indolent tumors compounds the already significant burden of disease and treatment can lead to long-term side effects including impotence and impaired urinary and/or bowel function. There is currently an unmet clinical need for diagnostic and/or prognostic tools that facilitate personalized prostate cancer treatment, and potentially reduce the clinical, economic and humanistic burden of invasive cancer treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12894-019-0448-6) contains supplementary material, which is available to authorized users. BioMed Central 2019-03-18 /pmc/articles/PMC6421711/ /pubmed/30885200 http://dx.doi.org/10.1186/s12894-019-0448-6 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Smith-Palmer, J. Takizawa, C. Valentine, W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada |
title | Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada |
title_full | Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada |
title_fullStr | Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada |
title_full_unstemmed | Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada |
title_short | Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada |
title_sort | literature review of the burden of prostate cancer in germany, france, the united kingdom and canada |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421711/ https://www.ncbi.nlm.nih.gov/pubmed/30885200 http://dx.doi.org/10.1186/s12894-019-0448-6 |
work_keys_str_mv | AT smithpalmerj literaturereviewoftheburdenofprostatecanceringermanyfrancetheunitedkingdomandcanada AT takizawac literaturereviewoftheburdenofprostatecanceringermanyfrancetheunitedkingdomandcanada AT valentinew literaturereviewoftheburdenofprostatecanceringermanyfrancetheunitedkingdomandcanada |